GO:0032556 pyrimidine deoxyribonucleotide binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032556 pyrimidine deoxyribonucleotide binding describes the molecular function of selectively binding deoxyribonucleotides that contain a pyrimidine base, namely dCTP, dCDP, dCMP, dTTP, dTDP, dTMP, and their deoxyuridine relatives.
• This binding activity is central to nucleotide pool homeostasis, DNA replication fidelity, and the allosteric control of enzymes such as ribonucleotide reductase and CTP/dCTP synthases.
• Pyrimidine deoxyribonucleotide binding proteins include polymerases, kinases, nucleotidases, and immune signaling receptors that sense nucleotide ligands.
• Imbalanced pyrimidine deoxyribonucleotide pools are mutagenic and are exploited therapeutically by antimetabolites such as 5-fluorodeoxyuridine monophosphate.
• CRISPR knockout, point-mutation, knock-in, and overexpression models allow causal testing of genes encoding pyrimidine deoxyribonucleotide binding proteins.
• EDITGENE provides end-to-end cell model and CRISPR library screening services to dissect pyrimidine deoxyribonucleotide binding in disease and immunity.
Description
Pyrimidine deoxyribonucleotide binding (GO:0032556) is a molecular function that enables a protein to selectively recognize and bind deoxyribonucleotides containing a pyrimidine base, including dCTP, dCDP, dCMP, dTTP, dTDP, dTMP, and related deoxyuridine derivatives. This binding event is not merely a passive interaction; it underlies allosteric regulation, substrate channeling, and signaling in nucleotide metabolism and DNA metabolism. Because pyrimidine deoxyribonucleotides are the direct precursors of DNA, proteins that bind them are essential for genome duplication, repair, and cell-cycle progression. Researchers study GO:0032556 to understand how cells maintain balanced deoxynucleotide pools, how antimetabolite drugs are recognized, and how nucleotide-sensing immune pathways are triggered. The function is also relevant to cancer biology, because altered pyrimidine deoxyribonucleotide binding can change drug sensitivity and mutation rates. In this article we integrate the QuickGO definition with verified PubMed literature to provide a research-grade overview of the mechanism, genes, diseases, and experimental models associated with GO:0032556.
pyrimidine deoxyribonucleotide binding At A Glance
| GO ID | GO:0032556 |
|---|---|
| GO term | pyrimidine deoxyribonucleotide binding |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Selective non-covalent binding of pyrimidine deoxyribonucleotides such as dCTP, dTTP, and their phosphorylated derivatives |
| Representative ligands | dCTP, dCDP, dCMP, dTTP, dTDP, dTMP, deoxyuridine phosphates |
| Biological context | Nucleotide pool homeostasis, DNA replication, DNA repair, allosteric regulation, and nucleotide-sensing immunity |
| Related disease areas | Cancer, antiviral and antimetabolite pharmacology, immune dysregulation |
| Experimental readouts | Binding assays, enzyme kinetics, CRISPR knockouts, structural biology |
What Is GO:0032556?
GO:0032556 pyrimidine deoxyribonucleotide binding is defined by QuickGO as the binding to a pyrimidine deoxyribonucleotide, any compound consisting of a pyrimidine deoxyribonucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the deoxyribose moiety. In practice, this means a protein domain or pocket physically interacts with molecules such as dCTP, dCDP, dCMP, dTTP, dTDP, dTMP, or deoxyuridine phosphates, without necessarily catalyzing a chemical reaction. The term is a molecular_function in the Gene Ontology and is distinct from pyrimidine ribonucleotide binding because the sugar moiety is 2-deoxyribose rather than ribose. Binding can be transient, as in allosteric regulation, or stable, as in enzyme-substrate complexes.
Why Is pyrimidine deoxyribonucleotide binding Important in Cell Biology?
Pyrimidine deoxyribonucleotide binding is important because it controls the availability and fidelity of the building blocks of DNA, and because it is the molecular event through which cells sense and respond to nucleotide signals. Proteins that bind these nucleotides regulate ribonucleotide reductase, thymidylate synthase, DNA polymerases, and immune receptors, so perturbations in this function can cause mutagenesis, chemoresistance, or immune dysfunction. Understanding GO:0032556 therefore informs cancer therapy, antiviral drug design, and the basic biology of genome maintenance.
• Maintains balanced dNTP pools required for accurate DNA replication and repair.
• Mediates allosteric feedback inhibition of ribonucleotide reductase by dTTP and dCTP.
• Enables substrate recognition by CTP/dCTP synthases and thymidylate synthase.
• Supports nucleotide-sensing immune signaling in bacteria and potentially in host defense.
• Determines sensitivity to antimetabolite drugs such as 5-fluorodeoxyuridine.
• Contributes to G-quadruplex regulation through Rev1 polymerase binding of deoxycytidine derivatives.
• Provides a mechanistic basis for nucleoside analog nanogel drug delivery.
• Links nucleotide pool imbalance to DNA repair defects and genome instability.
• Offers targets for CRISPR-based functional genomics in cancer and immunology.
• Enables structural and biophysical dissection of ligand specificity.
Molecular Mechanism of pyrimidine deoxyribonucleotide binding
Ligand recognition and binding pocket architecture
In simple terms: Proteins use a shaped pocket to grab pyrimidine deoxyribonucleotides.
Pyrimidine deoxyribonucleotide binding proteins typically contain a Rossmann-like or alpha/beta pocket that positions the pyrimidine base, the 2-deoxyribose sugar, and the phosphate groups through hydrogen bonds and electrostatic interactions. Structural studies of bifunctional CTP/dCTP synthase show how the enzyme discriminates between ribo- and deoxyribonucleotides by reading the sugar 2'-position and the base functional groups. In Rev1 polymerase, the pocket accommodates deoxycytidine derivatives and contributes to G-quadruplex disruption. These binding events are non-covalent and reversible, allowing rapid responses to changing nucleotide pools.
Allosteric regulation of nucleotide metabolism
In simple terms: Binding of one nucleotide can switch an enzyme on or off.
Ribonucleotide reductase is allosterically regulated by dTTP and dCTP binding at the specificity site, which shifts substrate preference and maintains balanced dNTP pools. This feedback control is a classic example of pyrimidine deoxyribonucleotide binding acting as a regulatory signal rather than a catalytic step. Disruption of this allostery leads to pool imbalance and increased mutation rates.
Substrate channeling and catalysis
In simple terms: Some enzymes bind the nucleotide and then chemically modify it.
Thymidylate synthase binds 5-fluorodeoxyuridine monophosphate (5-FdUMP) and forms a covalent complex that self-inactivates the enzyme in a tetrahydrofolate-dependent manner. CTP/dCTP synthase binds dCTP and related nucleotides to catalyze amination or deamination reactions. These examples show that GO:0032556 binding is often a prerequisite for catalysis and can be targeted by mechanism-based inhibitors.
Nucleotide-sensing and signal transduction
In simple terms: Binding of deoxynucleotides can trigger a cellular alarm.
Bacterial immunity systems use nucleotide signals to coordinate activation and inhibition of defense pathways, demonstrating that pyrimidine deoxyribonucleotide binding can function in signal transduction. In eukaryotes, nucleotide-sensing pathways intersect with DNA damage responses and immune signaling, although the precise receptors remain an active area of research. This signaling role expands the functional scope of GO:0032556 beyond metabolism.
Pharmacological modulation and nucleoside analogs
In simple terms: Drugs can mimic these nucleotides and block their binding.
Nucleoside analogs such as 5-fluorodeoxyuridine and other antimetabolites are designed to bind pyrimidine deoxyribonucleotide-binding enzymes and inhibit DNA synthesis. Polymeric nanogel formulations improve delivery of these analogs and enhance their interaction with target proteins. Understanding the binding specificity of GO:0032556 proteins is therefore central to rational drug design.
Key Genes Involved in GO:0032556 pyrimidine deoxyribonucleotide binding
The following genes encode proteins with demonstrated or inferred pyrimidine deoxyribonucleotide binding activity, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RRM1 | Ribonucleotide reductase subunit; binds dTTP/dCTP for allosteric regulation | dNTP pool balance and cancer drug resistance |
| RRM2 | Ribonucleotide reductase subunit; binds deoxyribonucleotides | Cell cycle and DNA synthesis |
| TYMS | Thymidylate synthase; binds 5-FdUMP and dUMP | Antimetabolite chemotherapy |
| CTPS1 | CTP/dCTP synthase; binds dCTP and UTP | Pyrimidine biosynthesis and immune function |
| CTPS2 | CTP/dCTP synthase isoform; binds dCTP | Nucleotide metabolism |
| REV1 | Translesion polymerase; binds deoxycytidine derivatives | G-quadruplex disruption and mutagenesis |
| POLA1 | DNA polymerase alpha; binds dCTP/dTTP | DNA replication |
| POLB | DNA polymerase beta; binds dNTPs | Base excision repair |
| DCTD | dCMP deaminase; binds dCMP | Pyrimidine salvage |
| NT5C | 5'-nucleotidase; binds deoxyribonucleotides | Nucleotide catabolism |
| DUT | dUTPase; binds dUTP | Prevents uracil misincorporation |
| TK1 | Thymidine kinase; binds dT | Salvage pathway and proliferation marker |
| DCK | Deoxycytidine kinase; binds dC and analogs | Nucleoside analog activation |
| CMPK1 | UMP-CMP kinase; binds dCMP | Pyrimidine nucleotide synthesis |
| NME1 | Nucleoside diphosphate kinase; binds dTDP | Nucleotide homeostasis |
| SAMHD1 | Binds dNTPs and regulates pools | Antiviral restriction and immunity |
| STING1 | Binds cyclic dinucleotides; related nucleotide sensing | Innate immunity |
| POLH | DNA polymerase eta; binds dNTPs | Translesion synthesis |
How Is pyrimidine deoxyribonucleotide binding Regulated?
Pyrimidine deoxyribonucleotide binding is regulated at multiple levels. Allosteric feedback by dTTP and dCTP controls ribonucleotide reductase activity, ensuring balanced dNTP pools. Enzyme abundance is regulated by cell-cycle-dependent transcription and proteolysis, as seen for thymidylate synthase and ribonucleotide reductase. Post-translational modifications and subcellular localization further modulate binding to deoxyribonucleotides. In immune signaling, nucleotide-binding receptors are regulated by second messengers and protein-protein interactions. Finally, pharmacological inhibitors and nucleoside analogs can competitively or covalently interfere with binding.
pyrimidine deoxyribonucleotide binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TYMS | Colorectal cancer and 5-FU resistance | HCT116 TYMS knockout and point-mutation knock-in |
| RRM1 | Lung cancer and gemcitabine resistance | A549 RRM1 overexpression and knockout |
| REV1 | Mutagenesis and G-quadruplex-related genome instability | U2OS REV1 knockout and tagged knock-in |
| SAMHD1 | Antiviral restriction and Aicardi-Goutieres syndrome | THP-1 SAMHD1 knockout |
| CTPS1 | Immunodeficiency and pyrimidine biosynthesis | Jurkat CTPS1 point-mutation knock-in |
Cancer and chemoresistance
Altered pyrimidine deoxyribonucleotide binding contributes to cancer progression and resistance to antimetabolite drugs. For example, thymidylate synthase binding of 5-FdUMP mediates the cytotoxic effect of 5-fluorouracil, and mutations or expression changes in this binding interface can cause chemoresistance. Ribonucleotide reductase allosteric regulation by dTTP/dCTP is also linked to tumor growth and drug sensitivity. Targeting these binding events is a major therapeutic strategy.
Genome instability and DNA repair defects
Imbalanced pyrimidine deoxyribonucleotide pools caused by defective binding or regulation lead to misincorporation, DNA repair defects, and genome instability. Rev1 polymerase binding of deoxycytidine derivatives affects G-quadruplex stability and mutagenesis. These mechanisms connect GO:0032556 to cancer predisposition and aging.
Immune dysfunction and host defense
Nucleotide-sensing immune pathways rely on pyrimidine deoxyribonucleotide binding to activate or inhibit defense responses. Bacterial immunity systems use nucleotide signals to coordinate CRISPR-associated and other defense mechanisms. In humans, SAMHD1 binds dNTPs to restrict viral replication, linking nucleotide binding to antiviral immunity.
Pharmacology of nucleoside analogs
Many antiviral and anticancer nucleoside analogs require binding to pyrimidine deoxyribonucleotide-binding proteins for activation or inhibition. Nanogel formulations improve delivery and target engagement. Understanding the structural basis of binding accelerates rational drug design.
From pyrimidine deoxyribonucleotide binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of pyrimidine deoxyribonucleotide binding affect dNTP pools? | CRISPR knockout of RRM1 or TYMS in cancer cell lines |
| Does a specific binding-site residue control allostery? | Point mutation of RRM1 allosteric site |
| Can a disease-associated mutation alter ligand affinity? | Knock-in of patient-derived mutations in CTPS1 or SAMHD1 |
| Where is the binding protein localized? | Tagged knock-in with fluorescent or epitope tag |
| Does overexpression drive chemoresistance? | Doxycycline-inducible overexpression of TYMS or RRM1 |
| Which genes modulate nucleotide analog sensitivity? | Genome-wide CRISPR library screening |
How to Study the pyrimidine deoxyribonucleotide binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Isothermal titration calorimetry | Binding affinity and stoichiometry | Characterizing dCTP binding to CTPS1 |
| X-ray crystallography | Three-dimensional structure of protein-ligand complex | Visualizing allosteric site of RRM1 |
| CRISPR knockout | Loss-of-function phenotype | Testing TYMS dependence in cancer cells |
| CRISPR point mutation | Effect of specific residue change | Dissecting Rev1 deoxycytidine binding |
| Metabolomics (LC-MS) | Intracellular dNTP concentrations | Measuring pool imbalance after gene editing |
| RNA-seq | Transcriptional response to nucleotide stress | Identifying compensatory pathways |
| Proteomics | Protein interaction partners | Finding nucleotide-binding complexes |
| Fluorescence microscopy | Subcellular localization | Tracking tagged knock-in proteins |
Binding and kinetic assays
Direct binding of pyrimidine deoxyribonucleotides can be measured by isothermal titration calorimetry, surface plasmon resonance, or fluorescence polarization using purified proteins. Enzyme kinetics with dCTP or dTTP as substrates or allosteric effectors reveal functional consequences. These assays are essential for validating hits from structural or screening studies.
Structural biology
X-ray crystallography and cryo-electron microscopy of CTP/dCTP synthase and Rev1 polymerase have revealed the atomic details of pyrimidine deoxyribonucleotide binding. These structures guide mutagenesis and drug design.
CRISPR functional genomics
Genome-wide CRISPR knockout and activation screens identify genes whose loss or gain alters sensitivity to nucleoside analogs or affects dNTP pools. Point-mutation knock-in models can dissect specific binding residues.
Metabolomics and nucleotide pool analysis
Liquid chromatography-mass spectrometry quantifies dNTP pools in cells with CRISPR-edited pyrimidine deoxyribonucleotide binding proteins. This readout links molecular binding to cellular metabolism.
How CRISPR Can Be Used to Study GO:0032556 pyrimidine deoxyribonucleotide binding
Knockout
CRISPR knockout of genes encoding pyrimidine deoxyribonucleotide binding proteins, such as TYMS or RRM1, causes dNTP pool imbalance and growth defects, validating their essential roles. Knockout cell lines are used to test drug sensitivity and synthetic lethality.
Point Mutation
Point mutations in the binding pocket of RRM1 or REV1 can abolish allosteric regulation or ligand recognition without deleting the protein, allowing precise structure-function analysis. These models are ideal for dissecting disease-associated variants.
Knock-in
Knock-in of tagged or patient-derived alleles enables visualization and functional study of pyrimidine deoxyribonucleotide binding proteins in their native genomic context. This approach is particularly useful for SAMHD1 and CTPS1 disease variants.
Overexpression
Overexpression of TYMS or RRM1 mimics the elevated nucleotide metabolism seen in tumors and confers resistance to antimetabolites. Inducible overexpression systems allow dose-dependent studies of binding-mediated phenotypes.
How EDITGENE Supports pyrimidine deoxyribonucleotide binding Research
Researchers studying pyrimidine deoxyribonucleotide binding-related genes often need to determine whether a candidate gene is causally involved in nucleotide pool regulation, drug response, or immune signaling. EDITGENE provides the CRISPR cell models and screening services required to move from correlation to causation.
Contact EDITGENE today to design your custom CRISPR model for pyrimidine deoxyribonucleotide binding research.
Frequently Asked Questions About pyrimidine deoxyribonucleotide binding
What is pyrimidine deoxyribonucleotide binding?
It is the molecular function defined by GO:0032556, in which a protein selectively binds deoxyribonucleotides containing a pyrimidine base, such as dCTP, dTTP, and their phosphorylated derivatives.
What genes are involved in pyrimidine deoxyribonucleotide binding?
Key genes include RRM1, RRM2, TYMS, CTPS1, CTPS2, REV1, POLA1, POLB, DUT, TK1, DCK, CMPK1, NME1, SAMHD1, and STING1, based on published studies.
What is the GO ID for pyrimidine deoxyribonucleotide binding?
The Gene Ontology identifier is GO:0032556, and it belongs to the molecular_function ontology.
How is pyrimidine deoxyribonucleotide binding regulated?
It is regulated by allosteric feedback from dTTP and dCTP, cell-cycle-dependent expression, post-translational modifications, and pharmacological inhibitors.
Which diseases are linked to pyrimidine deoxyribonucleotide binding?
Cancer chemoresistance, genome instability, antiviral immunity defects, and Aicardi-Goutieres syndrome have been linked to altered binding of pyrimidine deoxyribonucleotides.
What experimental methods study pyrimidine deoxyribonucleotide binding?
Isothermal titration calorimetry, X-ray crystallography, CRISPR knockout and point mutation, metabolomics, and RNA-seq are commonly used.
Can CRISPR be used to study pyrimidine deoxyribonucleotide binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect the function of genes encoding these binding proteins.
What is the role of thymidylate synthase in pyrimidine deoxyribonucleotide binding?
Thymidylate synthase binds 5-fluorodeoxyuridine monophosphate and dUMP, and this binding leads to enzyme self-inactivation in a tetrahydrofolate-dependent manner.
How does ribonucleotide reductase bind pyrimidine deoxyribonucleotides?
Ribonucleotide reductase binds dTTP and dCTP at allosteric sites to regulate substrate specificity and maintain balanced dNTP pools.
Why is pyrimidine deoxyribonucleotide binding important for cancer therapy?
Many antimetabolite drugs, such as 5-fluorouracil, require binding to pyrimidine deoxyribonucleotide-binding enzymes for their cytotoxic effects, and altered binding can cause resistance.
Conclusion
GO:0032556 pyrimidine deoxyribonucleotide binding is a fundamental molecular function that connects nucleotide metabolism, DNA replication, immune signaling, and drug action. Proteins such as ribonucleotide reductase, thymidylate synthase, CTP/dCTP synthase, and Rev1 use this binding activity to maintain genome integrity and respond to cellular stress. Dysregulation of these interactions contributes to cancer, chemoresistance, and immune disorders, making them attractive therapeutic targets. CRISPR-based cell models and functional genomics provide powerful tools to dissect the causal roles of pyrimidine deoxyribonucleotide binding genes in health and disease.
References
- 1. Yamaguchi S et al.. 2026. Nucleotide signals coordinate activation and inhibition of bacterial immunity.. Nature 652(8111):978-985 PMID: 41708866
- 2. Guo CJ et al.. 2024. Structural Basis of Bifunctional CTP/dCTP Synthase.. J Mol Biol 436(20):168750 PMID: 39173734
- 3. Reichard P. 1985. Ribonucleotide reductase and deoxyribonucleotide pools.. Basic Life Sci 31:33-45 PMID: 3888178
- 4. Vinogradov SV. 2007. Polymeric nanogel formulations of nucleoside analogs.. Expert Opin Drug Deliv 4(1):5-17 PMID: 17184158
- 5. Sobich J et al.. 2019. Thymidylate synthase-catalyzed, tetrahydrofolate-dependent self-inactivation by 5-FdUMP.. Arch Biochem Biophys 674:108106 PMID: 31520592
- 6. Eddy S et al.. 2014. Human Rev1 polymerase disrupts G-quadruplex DNA.. Nucleic Acids Res 42(5):3272-85 PMID: 24366879
- 7. Holliday R. 1985. Aspects of DNA repair and nucleotide pool imbalance.. Basic Life Sci 31:453-60 PMID: 3888183
